Anti-biofilm activity of dalbavancin against methicillin-resistant Staphylococcus aureus (MRSA) isolated from human bone infection

References

• WHO. Critically important antimicrobials for human medicine, 6th revision 2018. 2019. [accessed 2020 Feb 12]. Available from: https://www.who.int/foodsafety/areas_work/antimicrobial-resistance/cia/en/.
   Google Scholar
• Tatarkiewicz J, Staniszewska A, Bujalska-Zadrożny M. New agents approved for treatment of acute staphylococcal skin infections. Arch Med Sci. 2016;12(6):1327–36.
   PubMed Web of Science ®Google Scholar
• Arena F, Romanini E, Rosi E, Salomone C, Tucci G, Pempinello C, Fantoni M. The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery. J Chemother. 2018;30(3):131–9.
   PubMed Web of Science ®Google Scholar
• Esposito S, Noviello S, Leone S. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Le Infezioni Med. 2015;4:313–7.
   Google Scholar
• Kussmann M, Karer M, Obermueller M, Schmidt K, Barousch W, Moser D, Nehr M, Ramharter M, Poeppl W, Makristathis A, et al. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis. Emerg Microbes Infect. 2018;7(1):1–10.
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. AAC. 2009;53(3):1260–3.
   Google Scholar
• Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: Report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis. 2013;75(3):304–7.
   PubMed Web of Science ®Google Scholar
• Citron DM, Tyrrell KL, Goldstein EJC. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains. Diagn Microbiol Infect Dis. 2014;79(4):438–40.
   PubMed Web of Science ®Google Scholar
• Gomes D, Pereira M, Bettencourt AF. Osteomyelitis: An overview of antimicrobial therapy. Braz J Pharm Sci. 2013;49(1):13–27.
   Web of Science ®Google Scholar
• Paharik AE, Horswill AR. The Staphylococcal Biofilm: Adhesins, Regulation, and Host Response. Microbiol Spectr. 2016. DOI:https://doi.org/10.1128/9781555819286.ch19
   Google Scholar
• Kavanagh N, Ryan EJ, Widaa A, Sexton G, Fennell J, O’rourke S, et al. Staphylococcal Osteomyelitis: Disease Progression, Treatment Challenges, and Future Directions. 2018. Available from: http://cmr.asm.org/.
   Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing. CLSI supplement M100. 27th ed. Wayne, PA: Clin Lab Stand Inst; 2017.
   Google Scholar
• Silva V, Almeida F, Carvalho JA, Castro AP, Ferreira E, Manageiro V, Tejedor-Junco MT, Caniça M, Igrejas G, Poeta P, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus EMRSA-15 clone as the predominant cause of diabetic foot ulcer infections in Portugal. Eur J Clin Microbiol Infect Dis. 2020;39(1):179–86.
   PubMed Web of Science ®Google Scholar
• Silva V, Almeida F, Silva A, Correia S, Carvalho JA, Castro AP, Ferreira E, Manageiro V, Caniça M, Igrejas G, et al. First report of linezolid-resistant cfr-positive methicillin-resistant Staphylococcus aureus in humans in Portugal. J Glob Antimicrob Resist. 2019;17:323–5.
   PubMed Web of Science ®Google Scholar
• Chen HJ, Hung WC, Tseng SP, Tsai JC, Hsueh PR, Teng LJ. Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother. 2010;54(12):4985–91.
   PubMed Web of Science ®Google Scholar
• Oliveira IM, Borges A, Borges F, Simões M. Repurposing ibuprofen to control Staphylococcus aureus biofilms. Eur J Med Chem. 2019;166:197–205.
   PubMed Web of Science ®Google Scholar
• Mottola C, Matias CS, Mendes JJ, Melo-Cristino J, Tavares L, Cavaco-Silva P, Oliveira M. Susceptibility patterns of Staphylococcus aureus biofilms in diabetic foot infections. BMC Microbiol. 2016;16(1):119.
   PubMedGoogle Scholar
• Bouras D, Doudoulakakis A, Tsolia M, Vaki I, Giormezis N, Petropoulou N, Lebessi E, Gennimata V, Tsakris A, Spiliopoulou I, et al. Staphylococcus aureus osteoarticular infections in children: An 8-year review of molecular microbiology, antibiotic resistance and clinical characteristics. J Med Microbiol. 2018;67(12):1753–60.
   PubMed Web of Science ®Google Scholar
• Peng K-T, Huang T-Y, Chiang Y-C, Hsu Y-Y, Chuang F-Y, Lee C-W, Chang P-J. Comparison of Methicillin-Resistant Staphylococcus aureus Isolates from Cellulitis and from Osteomyelitis in a Taiwan Hospital, 2016–2018. JCM. 2019;8(6):816.
   Google Scholar
• Silva V, Miranda C, Antão HS, Guimarães J, Prada J, Pires I, et al. Therapeutic potential of dalbavancin in a rat model of methicillin-resistant Staphylococcus aureus (MRSA)-osteomyelitis. Int J Antimicrob Agents. 2020;56(1):106021.
   PubMed Web of Science ®Google Scholar
• Xhemali X, Smith JR, Kebriaei R, Rice SA, Stamper KC, Compton M, Singh NB, Jahanbakhsh S, Rybak MJ. Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus. J Antimicrob Chemother. 2019; 74(1):82–6.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016). Int J Antimicrob Agents. 2018;51(4):608–11.
   PubMed Web of Science ®Google Scholar
• Kussmann M, Obermueller M, Berndl F, Reischer V, Veletzky L, Burgmann H, Poeppl W. Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model. Sci Rep. 2018;8(1):9661.
   Google Scholar
• Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849–55.
   PubMed Web of Science ®Google Scholar
• Goldstein BP, Draghi DC, Sheehan DJ, Hogan P, Sahm DF. Bactericidal activity and resistance development profiling of dalbavancin. AAC. 2007;51(4):1150–4.
   Google Scholar
• Mataraci E, Dosler S. In vitro activities of antibiotics and antimicrobial cationic peptides alone and in combination against methicillin-resistant Staphylococcus aureus biofilms. Antimicrob Agents Chemother. 2012;56(12):6366–71.
   PubMed Web of Science ®Google Scholar
• Žiemytė M, Rodríguez-Díaz JC, Ventero MP, Mira A, Ferrer MD. Effect of Dalbavancin on Staphylococcal Biofilms When Administered Alone or in Combination With Biofilm-Detaching Compounds. Front Microbiol. 2020;11:553.
   PubMed Web of Science ®Google Scholar
• Di PV, Ceccherini F, Sennati S, D’Agostino F, Arena F, D’Atanasio N, et al. In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times. Diagn Microbiol Infect Dis. 2020;96(2):114901.
   Web of Science ®Google Scholar
• Knafl D, Tobudic S, Cheng SC, Bellamy DR, Thalhammer F. Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Eur J Clin Microbiol Infect Dis. 2017;36(4):677–80.
   PubMed Web of Science ®Google Scholar
• Silva V, Antão HS, Guimarães J, Prada J, Pires I, Martins Â, et al. Efficacy of dalbavancin against MRSA biofilms in a rat model of orthopaedic implant-associated infection. J Antimicrob Chemother. 2020;75(8):2182–7.
   PubMed Web of Science ®Google Scholar
• Barnea Y, Lerner A, Aizic A, Navon-Venezia S, Rachi E, Dunne MW, Puttagunta S, Carmeli Y. Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis. J Antimicrob Chemother. 2016;71(2):460–3.
   PubMed Web of Science ®Google Scholar